UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040190
Receipt number R000045827
Scientific Title High flow nasal cannula on sleep apnea syndrome in stroke patients
Date of disclosure of the study information 2020/04/19
Last modified on 2020/08/27 09:40:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

High flow nasal cannula on sleep apnea syndrome in stroke patients

Acronym

High flow nasal cannula on sleep apnea syndrome in stroke patients

Scientific Title

High flow nasal cannula on sleep apnea syndrome in stroke patients

Scientific Title:Acronym

High flow nasal cannula on sleep apnea syndrome in stroke patients

Region

Japan


Condition

Condition

Stroke

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

High flow nasal cannula on sleep apnea syndrome in stroke patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Sleep efficiency, Rem sleep, Apnea-hypopnea index, Oxygen desaturation index

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Stroke

Key exclusion criteria

SAS with suspected other conditions (neuromuscular disease, heat failure, and narcolepsy), past history of SAS, catecholamine use which may affect the vascular tone, patients having unsuccessful recording in any WatchPat channel.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Nobuto
Middle name
Last name Nakanishi

Organization

Tokushima University Hospital

Division name

Emergency and Critical Care Medicine

Zip code

770-8503

Address

2-50-1 Kuramoto, Tokushima

TEL

088-633-9347

Email

nobuto_nakanishi@yahoo.co.jp


Public contact

Name of contact person

1st name Nobuto
Middle name
Last name Nakanishi

Organization

Tokushima University Hospital

Division name

Emergency and Critical Care Medicine

Zip code

770-8503

Address

2-50-1 Kuramoto, Tokushima

TEL

088-633-9347

Homepage URL


Email

nobuto_nakanishi@yahoo.co.jp


Sponsor or person

Institute

Tokushima University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Trial Center for Developmental therapeutics, Tokushima University Hospital

Address

2-50-1 Kuramoto, Tokushima

Tel

088-633-9294

Email

awachiken@tokushima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 04 Month 19 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/32832300/

Publication of results

Published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/32832300/

Number of participants that the trial has enrolled

12

Results

There were no differences in sleep-disordered breathing and sleep quality with and without HFNC therapy as follows: HFNC therapy vs control: apnea-hypopnea index 24.9 vs 21.3/h (p = 0.63), oxygen desaturation index 16.2 vs 12.9/h (p = 0.54), sleep efficiency 80.4 vs 87.1 (p = 0.28), percentage of REM sleep 19.4% vs 27.6% (p = 0.07). Two patients (17%) complained of discomfort among eight patients.

Results date posted

2020 Year 08 Month 27 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2020 Year 08 Month 25 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 04 Month 01 Day

Date of IRB

2016 Year 03 Month 01 Day

Anticipated trial start date

2017 Year 05 Month 01 Day

Last follow-up date

2020 Year 08 Month 27 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2020 Year 04 Month 18 Day

Last modified on

2020 Year 08 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045827


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name